|
Sponsors Forced to Repeat Studies in Light of Suspect Cetero Data
Some generic-drug makers who used the discredited contract research organization (CRO) Cetero Research will need to reanalyze or repeat studies, while others will need to conduct an independent third-party data audit, the FDA told drugmakers.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives